For the Inventor, By the Inventor

Enter assignee name

Pittsburgh, PA, United States of America

Knopp Biosciences, LLC

USPTO Granted Patents = 27

EPO Patents = 8

Trademarks = 2

Forward Citations = 113

Loading Chart...

Loading Chart...

33 inventors (with patents filed for the assignee):

Michael E Bozik (17 out of 26 patents)

Steven Dworetzky (11 out of 14 patents)

Thomas Petzinger, Jr (10 out of 17 patents)

4. Lynn Resnick (9 out of 13 patents)

5. George T Topalov (9 out of 31 patents)

6. Charles A Flentge (9 out of 13 patents)

7. David A Mareska (9 out of 24 patents)

8. James S Hale (9 out of 13 patents)

9. Justin K Belardi (8 out of 12 patents)

10. Scott S Harried (8 out of 30 patents)

11. Gregory Hebrank (6 out of 9 patents)

12. Wildon Farwell (6 out of 8 patents)

13. Kai Zhang (4 out of 4 patents)

14. Donald Archibald (3 out of 3 patents)

15. James L Mather (3 out of 3 patents)

27 patents: Sort by Forward Citations

1. 11261162 - KV7 channel activators compositions and methods of use (2022-03-01),

2. 11026928 - Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils (2021-06-08),

3. 10980783 - Compositions and methods for treating conditions related to increased eosinophils (2021-04-20),

4. 10906877 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2021-02-02),

5. 10851067 - Kv7 channel activators compositions and methods of use (2020-12-01),

6. 10828284 - Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils (2020-11-10),

7. 10526328 - Imidazo[4,5-b]pyridin-2-yl amides as Kv7 channel activators (2020-01-07),

8. 10456381 - Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders (2019-10-29),

9. 10385025 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2019-08-20),

10. 10383857 - Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils (2019-08-20),

11. 10383856 - Compositions and methods for treating conditions related to increased eosinophils (2019-08-20),

12. 10285981 - Compositions and methods for treating amyotrophic lateral sclerosis in responders (2019-05-14),

13. 10208003 - Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds (2019-02-19),

14. 10195183 - Compositions and methods for treating chronic urticaria (2019-02-05),

15. 10179774 - Synthesis of chirally purified substituted benzothiazole diamines (2019-01-15),

Knopp Biosciences is a leading biopharmaceutical company that is dedicated to discovering, developing, and commercializing transformative medicines to treat life-threatening respiratory and central nervous system diseases. With a focus on precision medicine and innovative drug delivery technologies, Knopp is committed to improving the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

27 Patents

#70 in Pittsburgh, PA

#451 in Pennsylvania

#11,991 in US

#23,273 in the World

Pittsburgh, PA, United States of America

Knopp Biosciences, LLC

Forward Citations = 113

33 inventors:

Michael E Bozik (17 out of 26 patents)

Steven Dworetzky (11 out of 14 patents)

Thomas Petzinger, Jr (10 out of 17 patents)

4. Lynn Resnick (9 out of 13 patents)

5. George T Topalov (9 out of 31 patents)

Please report any incorrect information to support@idiyas.com

Loading…